The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis
- PMID: 27640943
- DOI: 10.1016/j.ajog.2016.09.076
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis
Abstract
Background: Preeclampsia and fetal growth restriction are major causes of perinatal death and handicap in survivors. Randomized clinical trials have reported that the risk of preeclampsia, severe preeclampsia, and fetal growth restriction can be reduced by the prophylactic use of aspirin in high-risk women, but the appropriate dose of the drug to achieve this objective is not certain.
Objective: We sought to estimate the impact of aspirin dosage on the prevention of preeclampsia, severe preeclampsia, and fetal growth restriction.
Study design: We performed a systematic review and meta-analysis of randomized controlled trials comparing the effect of daily aspirin or placebo (or no treatment) during pregnancy. We searched MEDLINE, Embase, Web of Science, and Cochrane Central Register of Controlled Trials up to December 2015, and study bibliographies were reviewed. Authors were contacted to obtain additional data when needed. Relative risks for preeclampsia, severe preeclampsia, and fetal growth restriction were calculated with 95% confidence intervals using random-effect models. Dose-response effect was evaluated using meta-regression and reported as adjusted R2. Analyses were stratified according to gestational age at initiation of aspirin (≤16 and >16 weeks) and repeated after exclusion of studies at high risk of biases.
Results: In all, 45 randomized controlled trials included a total of 20,909 pregnant women randomized to between 50-150 mg of aspirin daily. When aspirin was initiated at ≤16 weeks, there was a significant reduction and a dose-response effect for the prevention of preeclampsia (relative risk, 0.57; 95% confidence interval, 0.43-0.75; P < .001; R2, 44%; P = .036), severe preeclampsia (relative risk, 0.47; 95% confidence interval, 0.26-0.83; P = .009; R2, 100%; P = .008), and fetal growth restriction (relative risk, 0.56; 95% confidence interval, 0.44-0.70; P < .001; R2, 100%; P = .044) with higher dosages of aspirin being associated with greater reduction of the 3 outcomes. Similar results were observed after the exclusion of studies at high risk of biases. When aspirin was initiated at >16 weeks, there was a smaller reduction of preeclampsia (relative risk, 0.81; 95% confidence interval, 0.66-0.99; P = .04) without relationship with aspirin dosage (R2, 0%; P = .941). Aspirin initiated at >16 weeks was not associated with a risk reduction or a dose-response effect for severe preeclampsia (relative risk, 0.85; 95% confidence interval, 0.64-1.14; P = .28; R2, 0%; P = .838) and fetal growth restriction (relative risk, 0.95; 95% confidence interval, 0.86-1.05; P = .34; R2, not available; P = .563).
Conclusion: Prevention of preeclampsia and fetal growth restriction using aspirin in early pregnancy is associated with a dose-response effect. Low-dose aspirin initiated at >16 weeks' gestation has a modest or no impact on the risk of preeclampsia, severe preeclampsia, and fetal growth restriction. Women at high risk for those outcomes should be identified in early pregnancy.
Keywords: aspirin; fetal growth restriction; meta-analysis; meta-regression; preeclampsia; pregnancy; systematic review.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment in
-
Preventing preeclampsia with aspirin: does dose or timing matter?Am J Obstet Gynecol. 2017 Feb;216(2):95-97. doi: 10.1016/j.ajog.2016.12.003. Am J Obstet Gynecol. 2017. PMID: 28148451 No abstract available.
Similar articles
-
Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of preeclampsia?Am J Obstet Gynecol. 2020 May;222(5):437-450. doi: 10.1016/j.ajog.2019.08.047. Epub 2019 Sep 5. Am J Obstet Gynecol. 2020. PMID: 31494125
-
Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials.Am J Perinatol. 2016 Jul;33(8):781-5. doi: 10.1055/s-0036-1572495. Epub 2016 Feb 23. Am J Perinatol. 2016. PMID: 26906184
-
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.Obstet Gynecol. 2010 Aug;116(2 Pt 1):402-414. doi: 10.1097/AOG.0b013e3181e9322a. Obstet Gynecol. 2010. PMID: 20664402
-
Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage.Am J Obstet Gynecol. 2018 May;218(5):483-489. doi: 10.1016/j.ajog.2017.12.238. Epub 2018 Jan 3. Am J Obstet Gynecol. 2018. PMID: 29305829 Review.
-
Prevention of Preeclampsia with Aspirin in Multiple Gestations: A Systematic Review and Meta-analysis.Am J Perinatol. 2016 May;33(6):605-10. doi: 10.1055/s-0035-1570381. Epub 2016 Jan 5. Am J Perinatol. 2016. PMID: 26731178 Review.
Cited by
-
Anemia in Pregnancy With CKD.Kidney Int Rep. 2024 Jan 11;9(5):1183-1197. doi: 10.1016/j.ekir.2024.01.015. eCollection 2024 May. Kidney Int Rep. 2024. PMID: 38707831 Free PMC article. Review.
-
Barriers and facilitators of adherence to low-dose aspirin during pregnancy: A co-produced systematic review and COM-B framework synthesis of qualitative evidence.PLoS One. 2024 May 3;19(5):e0302720. doi: 10.1371/journal.pone.0302720. eCollection 2024. PLoS One. 2024. PMID: 38701053 Free PMC article.
-
Aspirin for preeclampsia prevention in low- and middle-income countries: mind the gaps.AJOG Glob Rep. 2024 Apr 3;4(2):100352. doi: 10.1016/j.xagr.2024.100352. eCollection 2024 May. AJOG Glob Rep. 2024. PMID: 38694484 Free PMC article.
-
The optimal dosage of aspirin for preventing preeclampsia in high-risk pregnant women: A network meta-analysis of 23 randomized controlled trials.J Clin Hypertens (Greenwich). 2024 May;26(5):455-464. doi: 10.1111/jch.14821. Epub 2024 Apr 29. J Clin Hypertens (Greenwich). 2024. PMID: 38683867 Free PMC article.
-
Low dose aspirin prevents endothelial dysfunction in the aorta and foetal loss in pregnant mice infected with influenza A virus.Front Immunol. 2024 Apr 4;15:1378610. doi: 10.3389/fimmu.2024.1378610. eCollection 2024. Front Immunol. 2024. PMID: 38638436 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical